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Objective: To assess the distribution of serological markers in blood donors at the blood banks
of  the Fundac¸ão Centro de Hematologia e Hemoterapia de Minas Gerais (Hemominas), Brazil,
between January 2006 and December 2012.
Methods: This is a descriptive, retrospective study on blood donors screened using serological
tests  for markers of transmitted diseases at the state blood-banking network.
Results: Approximately 78.9% of the donors were considered eligible for the study after
clinical screening. Repeat donors represented 68.2% of the total sample, with males being
predominant as blood donors (66.8%). Total serological ineligibility was 3.05%, with total
anti-HBc being the most common marker (1.26%), followed by syphilis (0.88%) and human
immunodeﬁciency virus (0.36%). The prevalences of the markers for hepatitis C, Human
T-cell lymphotropic virus, Chagas disease and HBs-Ag were 0.15%, 0.09%, 0.13% and 0.18%,
respectively. The blood bank of Governador Valadares had the highest percentage of positive
anti-HBc donors (2.41%). With regard to human immunodeﬁciency virus, the blood bank of
Além Paraíba had the lowest percentage of positive donors while the blood banks of Juiz de
Fora and Betim had the highest percentages. The blood bank in the city of Montes Claros
had the highest prevalence of the marker for Chagas disease (0.69%).
Conclusions: Data on the proﬁle of serological ineligibility by the blood banks of the Fundac¸ão
Hemominas highlights the particularities of each region thereby contributing to measures
for  health surveillance and helping the blood donation network in its donor selection pro-
cedures aimed at improving blood transfusion safety.©  2016 Publis
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ntroduction
n Brazil, up to the 1960s, transfusion procedures were mostly
erformed by private hospital blood banks with no govern-
ental regulation. Paradoxically, the importance of blood as
ssential to the healthcare system was ﬁrstly noted with the
razilian Revolution of 1964. The army, in view of the immi-
ence of an armed conﬂict, found that stocks of blood and
omponents would be insufﬁcient to meet the needs in the
vent of armed combat.1 It was at that time that the ﬁrst public
nitiatives were taken in Brazil to try to normalize this activity.
The ﬁrst governmental act was the creation of a national
emotherapy commission aimed at setting a policy to reg-
late the blood collection procedure, including storage and
ransfusion.2 This commission formulated basic rules for
onors and blood transfusion by establishing the mandatory
erological screening tests needed for safe blood transfusions.
n 1980, the Federal Government implemented the National
rogram on Blood and Blood Derivatives with the participa-
ion of the civil society, in order to deﬁne a policy for blood
nd its components in Brazil, thus ensuring the availability,
afety and amount of these products.3
The regional blood-banking network of the state of Minas
erais was thus established in June 1982 with the objective of
mplementing the policies proposed by the National Program
n Blood and Blood Derivatives. In 1985, the blood-banking
etwork of Minas Gerais was ofﬁcially inaugurated, and
ecame known as the Centro de Hematologia e Hemoterapia
e Minas Gerais (Hemominas) and then Fundac¸ão Hemom-
nas four years later.4 Today, Fundac¸ão Hemominas is one
f the largest blood screening services in Brazil. It is com-
rised of 21 blood banks at the following sites: Além Paraíba,
elo Horizonte, Shopping Estac¸ão (Belo Horizonte), Betim,
iamantina, Juiz de Fora, Divinópolis, Governador Valadares,
atos de Minas, Sete Lagoas, Montes Claros, Uberlândia, Itu-
utaba, São João Del Rei, Manhuac¸u, Pouso Alegre, Hospital
úlia Kubitscheck (Belo Horizonte), Uberaba, Ponte Nova, Pas-
os, and Poc¸os de Caldas.5
Fundac¸ão Hemominas receives about 280,000 blood donors
er year and accounts for 91% of blood transfusions in Minas
erais. Epidemiological information on the diseases identiﬁed
mong blood donor candidates is important to gather data
n the blood banks of Fundac¸ão Hemominas, thus enabling a
eduction of the risks of disease transmission and ensuring the
uality of donated blood.6 With the increase in transfusions,
nd consequently in the transmission of blood-borne diseases,
emotherapy services are not only developing blood bank-
ng services, but researching these diseases. Subsequently
any  developments occurred within a few years including a
hift from paid to voluntary donation, and autologous blood
onations. The improvement in serological screening tests,
igorous transfusion requirements and standardization of pro-
edures have been essential for the safety of blood donation
nd transfusion.7
The transmission of infectious diseases through blood
ransfusion is characterized by a higher-risk of adverse reac-
ions in the blood recipient. The identiﬁcation of pathogens
y means of serological tests is one way of preventing the
issemination of these infectious agents during transfusion. 1 6;3  8(3):206–213 207
In Brazil, the Ministry of Health established that serological
tests must be performed for every blood donation regarding
the following pathogens: hepatitis B virus (HBV), hepatitis
C virus (HCV), human immunodeﬁciency virus (HIV) types
1 and 2, human T lymphotropic virus (HTLV) types 1 and
2, Trypanossoma cruzi, Treponema pallidum, and Plasmodium in
malaria-endemic areas (including molecular tests). Another
important procedure adopted to minimize the risks of con-
tamination is the clinical and epidemiological screening of the
candidates’ health status, habits, and risky behavior to help
to determine possible risks of blood donation in respect to the
health of donors and recipients.8–10 In order to standardize
the serological screening procedures throughout the state of
Minas Gerais, Fundac¸ão Hemominas created a serology cen-
ter in May 2005 to serve all 21 blood banks, thus accounting
for complementary serological screening and exams for both
donors and patients. Today, this serology center is one of
the largest donor screening laboratories in Brazil, performing
about two million tests per year.5
The objective of the present study is to describe the preva-
lence of serological screening markers among blood donor
candidates of the Fundac¸ão Hemominas between 2006 and
2012. The state of Minas Gerais is one of the 27 states of Brazil
with approximately 20 million inhabitants distributed among
853 towns. With 586,522,122 km2, the area of the state of Minas
Gerais, the fourth largest state of Brazil, corresponds to 6.89%
of the national territory; 2,525,800 km2 are in urban areas. The
city of Belo Horizonte, located in the central region, has a pop-
ulation of about 2.4 million people. The southern region of the
state is more  industrialized and economically developed, thus
it has good social indicators. On the other hand, the northern
region is one of the poorest regions in Brazil, because of the
drought and lack of effective government policies, with inefﬁ-
cient environmental sanitary services and high child mortality
and illiteracy rates.
Methods
Design
This descriptive retrospective study included all blood donors
screened using serological tests for makers of blood-borne
diseases at the Fundac¸ão Hemominas. The tests were manda-
tory during the period of the study from 2006 to 2012, even
for repeat donors as prior negative serological tests do not
spare them from possible serological ineligibility. The blood
bank at Poc¸os de Caldas was inaugurated in 2010. All data
were collected from computerized records of the Fundac¸ão
Hemominas.
The present study was approved in June 2013 by the
Research Ethics Committee of the Hospital das Clinicas of the
Faculdade de Medicina de Ribeirão Preto da Universidade de
São Paulo (FMRP-USP: #356.616).
Serological  screening  testsThe serological screening tests of blood samples were per-
formed in the serology center of the Fundac¸ão Hemominas.
The assays and kits used were the following:
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To determine HBsAg: PRISM (Abbott, CMIA) in 2006:
MonolisaTM HBsAg ULTRA (Biorad) in 2007–2012 and
ARCHITECT® HBsAg Assay (Abbott, CMIA) in 2012.
To determine human immune deﬁciency virus (HIV) –
method 1: PRISM (Abbott, CMIA) in 2006, GS HIV-1/HIV-2 PLUS
O EIA (Biorad) in 2007 and 2008, HIV Ag/Ab Combination (EIE,
Murex) in 2008 and 2009 and ARCHITECT® HIV Ag/Ab Combo
(Abbott, CMIA) in 2009–2012.
To determine human immune deﬁciency virus (HIV) –
method 2: HIV-1.2.0 (EIE, Murex) in 2006 and 2007,
GenscreenTM ULTRA HIV Ag-Ab (EIE, Biorad) in 2007–2012
and VITROS Anti-HIV 1+2 Assay (Ortho Clinical Diagnostics,
CMIA) in 2012.
To determine hepatitis C virus (HCV): Anti-HCV-version 4.0
(EIE, Murex) in 2006 and 2007, Hepatitis C Virus Encoded Anti-
gen (Recombinant c22-3, c200 and NS5) ORTHO® HCV Version
3.0 ELISA Test System in 2007–2009, HCV Ag/Ab Combination
(EIE, Murex) in 2009–2011, and MonolisaTM HCV Ag-Ab ULTRA
Assay (EIE, Biorad) in 2011 and 2012.
To determine hepatitis B core antibody (HBc): total anti-HBc
(IgG and IgM – ELISA Test System Ortho-Clinical Diagnos-
tics) in 2006 and 2007, MONOLISA Anti-HBc PLUS Assay (EIE,
Biorad) in 2007–2012 and ARCHITECT® Anti-HBc II (Abbott,
CMIA) in 2011 and 2012.
To determine Chagas disease: CHAGAS TEST ELISA BIOS
CHILE in 2006 and 2007 and GOLD ELISA CHAGAS (REM) in
2007–2012.
To determine human T-lymphotropic retroviruses (HTLV) I/II:
ELISA HTLV-I/II rp21 ELISA Ortho Diagnostics® System in
2006–2011, GOLD ELISA HTLV I/II (REM) in 2011 and 2012 and
ARCHITECT® rHTLV-I/II (Abbott, CMIA) in 2012.
To determine syphilis: ICE* Syphilis (Murex) in 2006 and 2007;
and Bioelisa Syphilis 3.0 (Biokit) in 2007–2012.
The present study did not use the conﬁrmatory test results
of initially positive results.
Results
A total of 2,361,879 blood donor candidates were interviewed
in Fundac¸ão Hemominas blood banks from January 2006 to
December 2012, with 1,864,553 donations being considered
eligible after clinical screening (Table 1). This screening con-
sists of evaluating the clinical and epidemiological history of
candidates, and their health status, habits and behavior to
determine whether they can be considered for blood dona-
tion without risking their health or that of the recipient.11,12
The overall percentage of donations from clinically eligible
donors of all the blood banks was 78.9%, ranging from 73.2%
in Montes Claros to 87.2% in Ponte Nova. The percentage of
donations from repeat donors (68.2%) was about twice that
of ﬁrst-time donors (31.8%) during the period of the study in
all blood banks except for Poc¸os de Caldas where 61.2% and
38.8% were ﬁrst-time and repeat donors, respectively (Table 2).
It should be remembered that the Poc¸os de Caldas blood bank
was inaugurated in 2010. The distribution of donations from
eligible donors stratiﬁed by gender found a predominance of
men  (66.2%), except for the blood bank of Diamantina where 2 0 1 6;3  8(3):206–213
50.2% of the donors were men  (Table 3). Table 3 shows the
distribution of eligible donors stratiﬁed by age.
Considering the clinically eligible donors, Figure 1 shows
the percentages of donations from donors with positive sero-
logy for syphilis, anti-HBc, Chagas disease, HTLV, HBsAG, HCV,
and HIV at each blood bank. The blood bank in Governador Val-
adares had the highest percentage of positive anti-HBc donors
(Figure 1b). Positivity for the serological marker for Chagas dis-
ease was more  common in the Montes Claros and Diamantina
blood banks; the cities are situated in the northern region of
the state and the Jequitinhonha Valley, respectively, where the
disease is endemic.13,14 Serological markers for HBs-Ag and
HCV were more  commonly observed in the Poc¸os de Caldas
blood bank (Figure 1e and f).
Discussion
Despite all the technological advances in recent years, the
production of blood components and blood derivatives still
depends on blood donation. However, the number of blood
donors does not fulﬁll the current demand in Brazil.15 In this
work, the mean percentage of clinically eligible donors in the
Hemominas blood banks was 78.9%, a value similar to that
reported by the annual report on the production of blood com-
ponents in 2013 as the percentage of clinical eligibility was
close to 81.4% nationally.16 Rohret et al.,17 conducted a study
at the Hospital Santo Angelo in Southern Brazil, and reported
a clinical eligibility of 73.6% for 2005–2015.
In this work, the percentage of donations from repeat
donors (68.2%) was approximately twice as high as for ﬁrst-
time donors (31.8%). These percentages are similar to those
observed throughout the country,16 as the percentages of
donors is estimated at 63.1% and 36.9% for repeat and ﬁrst-
time donors, respectively. However, a higher percentage of
ﬁrst-time donors (61.2%) was observed in the Poc¸os de Caldas
blood bank; this ﬁnding can be explained as the blood bank
was implanted only in 2010.
Among the eligible donors, there was a predominance of
men (66.2%). Santos and Macedo18 reported a percentage of
63.8% of male donors in a study conducted between 2005 and
2009 at the Campo Mourão blood bank, state of Paraná. Similar
data were reported by the Agencia Nacional de Vigilancia San-
itaria (ANVISA), whose study evaluated the proﬁle of donors
and non-donors throughout Brazil.19 Among the donor popu-
lation in Brazil, men  were found to be predominant (65.67%);
61.02% in southeastern Brazil, 63.97% in the southern region,
70.95% in the Northeast, 75.25% in northern Brazil and 75.96%
in the central-western region.
In the present study, 42.8% of eligible blood donors were
in the 18- to 29-year age group and 57.1% were older than
29 years old. Similar results are found across the country,16
with the majority of the blood donors being older than 29
years (57.08%). Other studies show that the number of blood
donations increases as the age decreases.18,20
Another factor affecting the decrease in the number of
blood donations is the rate of serological ineligibility. In 2002,
the serological ineligibility rate ranged from 10% to 20% in
Brazilian blood banks.21 This rate is very high compared to
developed countries.22 In Brazil, considering all the markers
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Table 1 – Distribution of blood donations according to eligibility and ineligibility of blood donor candidates.
Blood bank Blood donations
Eligible % Ineligibility % Dropouts % Total
Além Paraíba 23,313 81.3 5272 18.4 105 0.37 28,690
Betim 72,000 79.3 18,501 20.4 249 0.27 90,750
Diamantina 23,860 79.1 6151 20.4 167 0.55 30,178
Divinópolis 108,370 83.6 20,392 15.7 795 0.61 129,557
Belo Horizonte 485,827 73.7 156,701 23.8 16,888 2.56 659,416
Hospital Júlia Kubitscheck 81,283 76.1 25,031 23.4 454 0.43 106,768
Governador Valadares 91,756 78.7 22,881 19.6 1884 1.62 116,521
Ituiutaba 26,802 86.0 4231 13.6 115 0.37 31,148
Juiz de Fora 208,148 82.6 42,479 16.9 1425 0.57 252,052
Manhuac¸u 38,575 79.3 9753 20.1 314 0.65 48,642
Montes Claros 114,375 73.2 40,867 26.2 1023 0.65 156,265
Passos 47,424 85.3 7983 14.4 200 0.36 55,607
Pouso Alegre 88,328 83.2 17,151 16.2 668 0.63 106,147
Patos de Minas 46,093 82.9 9347 16.8 154 0.28 55,594
Poc¸os de Caldasa 19,481 79.5 4897 20.0 132 0.54 24,510
Ponte Nova 42,405 87.2 6059 12.5 167 0.34 48,631
São João del Rei 39,938 86.5 6059 13.1 161 0.35 46,158
Sete Lagoas 59,788 82.3 12,561 17.3 317 0.44 72,666
Uberaba 108,578 82.3 22,435 17.0 966 0.73 131,979
Uberlândia 138,209 81.0 31,745 18.6 646 0.38 170,600
Total 1,864,553 78.9 470,496 19.9 26,830 1.14 2,361,879
a From 2010 to 2012.
Table 2 – Distribution of blood donors as ﬁrst-time or repeat donors.
Unit Blood donations
First-time donors % Repeat donor % Total
Além Paraíba 8119 28.3 20,571 71.7 28,690
Betim 35,393 39.0 55,358 61.0 90,750
Diamantina 11,468 38.0 18,710 62.0 30,178
Divinópolis 40,940 31.6 88,617 68.4 129,557
Belo Horizonte 216,948 32.9 442,468 67.1 659,416
Hospital Júlia Kubitscheck 45,803 42.9 60,965 57.1 106,768
Governador Valadares 35,888 30.8 80,633 69.2 116,521
Ituiutaba 7631 24.5 23,517 75.5 31,148
Juiz de Fora 68,306 27.1 183,746 72.9 252,052
Manhuac¸u 13,377 27.5 35,265 72.5 48,642
Montes Claros 44,536 28.5 111,729 71.5 156,265
Passos 16,015 28.8 39,592 71.2 55,607
Pouso Alegre 38,850 36.6 67,297 63.4 106,147
Patos de Minas 14,899 26.8 40,695 73.2 55,594
Poc¸os de Caldasa 15,000 61.2 9510 38.8 24,510
Ponte Nova 13,908 28.6 34,723 71.4 48,631
São João del Rei 21,140 45.8 25,018 54.2 46,158
Sete Lagoas 21,872 30.1 50,794 69.9 72,666
Uberaba 33,391 25.3 98,588 74.7 131,979
Uberlândia 47,768 28.0 122,832 72.0 170,600
Total 751,253 31.8 1,610,626 68.2 2,361,879
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tudied, the mean rate of serological ineligibility in 2013 was
.43%.14 Similar data were found in the present work, as the
ate of serological ineligibility at the Fundac¸ão Hemominas
as 3.05%. The frequent changes in the brands of screeningest kits due to the bidding norms that have to be followed by
overnment blood banks to purchase products, contributed
o the serological ineligibility. This phenomenon occurs evenwhen high-sensitivity and speciﬁcity tests are used. Different
test kit brands produce different false-positive rates and, con-
sequently, it is more  likely that the results of a healthy blood
donor are positive to at least one of the brands used. This
would not happen if the same brand of kit were always used.21
The present study describes the asymmetry found in the
different blood banks regarding the distribution of serological
210  rev bras hematol hemoter. 2 0 1 6;3  8(3):206–213
Table 3 – Distribution of blood donors stratiﬁed by gender and age.
Unit Eligible to donate blood Gender (%) Age (%)
Men Women 18–29 years Older than 29 Under 18
Além Paraíba 23,313 80.5 19.5 31.6 68.4 –
Betim 72,000 61.7 38.3 42.2 57.7 0.03
Diamantina 23,860 50.2 49.8 55.9 44.1 0.05
Divinópolis 108,370 67.6 32.4 55.9 44.1 0.05
Belo Horizonte 485,827 63.9 36.1 52.1 47.9 0.06
Hospital Júlia Kubitscheck 81,283 66.6 33.4 45.4 54.5 0.03
Governador Valadares 91,756 65.5 34.5 40.0 59.9 0.10
Ituiutaba 26,802 66.9 33.1 43.4 56.5 0.10
Juiz de Fora 208,148 66.6 33.4 40.6 59.3 0.10
Manhuac¸u 38,575 73.2 26.8 47.2 52.8 0.02
Montes Claros 114,375 59.5 40.5 37.5 62.4 0.09
Passos 47,424 74.6 25.4 54.0 45.9 0.05
Pouso Alegre 88,328 76.6 23.4 37.2 62.7 0.08
Patos de Minas 46,093 64.7 35.3 35.3 64.6 0.05
Poc¸os de Caldas (a) 19,481 69.8 30.2 39.9 60.0 0.11
Ponte Nova 42,405 68.5 31.5 40.5 59.4 0.13
São João del Rei 39,938 69.3 30.7 38.2 61.6 0.16
Sete Lagoas 59,788 66.8 33.2 45.8  54.0 0.13
Uberaba 108,578 68.7 31.3 45.2 54.7 0.11
Uberlândia 138,209 65.9 34.1 43.5 56.5 0.07
 Total 1,864,553 66.2
a From 2010 to 2012.
markers for syphilis, anti-HBc, Chagas disease, HTLV, HBsAG,
HCV, and HIV. Of the 1,864,553 clinically eligible donors
referred for serological testing between 2006 and 2012, the
total anti-HBc (IgM/IgG) was the commonest serological
marker found (1.12% of blood donors) followed by syphilis
(0.98% of the study population). Data from a national sur-
vey in 2012 on the distribution of serological ineligibility due
to blood-borne disease markers reported a predominance
of anti-HBc (1.47%), followed by syphilis (0.67%), and HIV
(0.36%).16 In the northern region, approximately 5.16% of blood
donors are ineligibility because of serological results, with the
prevalence of the anti-HBc marker being 3.77%.16 On the other
hand, ineligibility due to syphilis in this region of Brazil (0.26%)
is far lower than the national average (0.67%). The highest rates
in Brazil for HIV and HTLV markers are in the northeastern
region (0.66% and 0.28% of blood donors, respectively). Over-
all ineligibility in this region is 4.39%. The central-western
region has a prevalence of HIV markers of 0.26%, the lowest
rate found in Brazil. Total serological ineligibility in this region
is 2.76%. Southeastern Brazil has the lowest rate of serologi-
cal ineligibility (2.68%), whereas the southern region has the
second-highest prevalence of anti-HBc markers (1.94%).16
In the study by Salles et al.21 who  evaluated blood donors
at the Fundac¸ão Pro-Sangue, the blood bank in São Paulo,
the prevalence of markers for syphilis was 1.1% between
1992 and 2001. The authors used two simultaneous tests to
investigate syphilis infections [enzyme immunoassay (EIA)
and venereal disease research laboratory (VDRL)]. Using dif-
ferent screening algorithms, Baião23 identiﬁed different rates
at the blood-banking network of Santa Catarina (HEMOSC).
From January 2009 to July 2011, using VDRL for screening
and ELISA and FTA-ABS as conﬁrmatory tests, 0.28% of pos-
itive results were found for syphilis. Between July 2011 and33.8 44.5 55.4 0.06
September 2012, 0.68% of positive results were reported for
syphilis using chemiluminescent microparticle immunoassay
(CMIA) to screen and VDRL and FTA-ABS to conﬁrm positive
test results. Soussumi,24 using non-treponemal anti-bodies
(Reaginas) to screen for syphilis, found a prevalence of 1.3%
among ﬁrst-time blood donors attending the blood bank of
Ribeirão Preto between 1996 and 2001. However, Rodrigues25
reported a prevalence of 0.61% for syphilis in blood donors
of the blood bank of Goiás between 2002 and 2011 using a
non-treponemal test (VDRL). In another study performed at
the Fundac¸ão de Hematologia e Hemoterapia do Amazonas
(HEMOAM) between 2000 and 2004, Ferreira et al.26 also used
a VDRL test and found a prevalence of 1.98%.
There is signiﬁcant variability in the prevalence of HCV
among blood donors (ranging from 0.34% to 1.8%) reported by
Brazilian studies.27–29 Comparisons between the prevalence of
markers in different services and regions should be cautious,
as they can vary due to the use of different serological tech-
niques as well as by the use or not of conﬁrmatory tests.28
The prevalence of HCV markers in the Fundac¸ão Hemominas
was 0.15%, with the blood bank at Poc¸os de Caldas having the
highest rate (0.24%) and the blood banks of Diamantina and
Patos de Minas having the lowest frequencies. According to
the annual report on the production of blood components pub-
lished in 2013,16 the prevalences of HCV markers in the states
of Tocantins (0.09%) and Santa Catarina (0.14%) were similar
to the rate found by the Fundac¸ão Hemominas (0.15%).
In this work, the prevalence of the HTLV  marker was
0.086%. The blood bank of Passos had the lowest rate (0.05%),
whereas the blood banks of Governador Valadares and Montes
Claros had the highest rates (0.10%). The seropositivity for
HTLV is associated with history of blood transfusion, and the
level of schooling, it serves as a socioeconomic indicator and
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Figure 1 – Distribution of serological markers per blood bank of the Fundac¸ão Hemominas between 2006 and 2012.
oter.
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of the use of non-intravenous illicit drugs. This highlights the
importance of monitoring and reﬁning the process of blood
donor selection.30
There were signiﬁcant differences in the prevalences of
anti-HBc markers between some blood banks. The blood bank
of Governador Valadares had the highest rate of anti-HBc pos-
itive donors (2.41%); the prevalence was signiﬁcantly higher
than the other six blood banks. The blood bank of São João
Del Rei had the lowest rate of positive results for this marker
(0.61%). One hypothesis for the high prevalence of anti-HBc in
the middle region of the Vale do Rio Doce may be the prox-
imity to the states of Bahia and Espírito Santo that reported
positive rates for anti-HBc of 2.97% and 1.81%, respectively.
According to the annual report on the production of blood
components from 2013,16 the prevalence of the HBs-Ag marker
in Brazil ranged from 0.07% in the state of Espírito Santo to
0.43% in the state of Paraíba. The state of São Paulo had the
lowest rate for anti-HBc (0.76%), whereas the highest rates
were reported in Rondônia (4.38%) and Acre (4.33%). Despite
evidence that immunization against hepatitis B virus can
produce an immune response, the anti-HBc marker is not
considered a neutralizing antibody, and its presence does not
indicate recovery from hepatitis B infection.31 Even so, the
exclusion of anti-HBc-positive donors is a controversial issue
as a high number of these donors are not allowed to donate
blood and there is evidence of false-positive results. In any
case, it should be stressed that donors who are positive only
for the hepatitis B marker are deﬁnitely considered ineligible
for donation.28 On the other hand, anti-HBc is an important
marker to detect occult hepatitis B, which is characterized
by the presence of HBV DNA in the blood serum of HBs-Ag-
negative individuals.32
In this work, the prevalence of the marker of Chagas dis-
ease for research purposes was 0.18%. Data from the annual
report on the production of blood components in 201314
reported that the prevalence of Chagas disease in Brazil ranged
from 0.02% in the state of Espírito Santo to 0.54% in the state
of Rio de Janeiro. According to Lacaz,33 in the state of Minas
Gerais, where Chagas disease was discovered, the epidemic
is high as the parasite has domestic habits, and is found
in virtually all the state. However, there has been a great
decrease in the occurrence of new cases of Chagas disease
in recent decades. This was possibly thanks to the epidemio-
logical surveillance practiced in communities to control vector
transmission, allied with the National Program for Chagas Dis-
ease Control and rural socioeconomic factors. In fact, not only
was a rural exodus observed, but also improvement in income
and housing conditions, the supply of electricity, and access
to education and healthcare.34 However, these improvements
were not as signiﬁcant in the northern semi-arid region of
the state of Minas Gerais, where the socioeconomic condi-
tions of the local population are still precarious and worrying,
mainly in the rural zone, thus it is considered one of the poo-
rest regions of Brazil. These conditions may account for the
re-emergence of Chagas disease in this region, as its spatial
distribution is coincident with that of other poor populations
as the disease is directly related to socioeconomic conditions.
The prevalence of HIV markers for research purposes was
0.052% in this study. From 2003 to 2013, the distribution of inel-
igible blood donors who were positive for HIV (types 1 and 2) 2 0 1 6;3  8(3):206–213
in the ﬁve regions of Brazil were 0.02% and 10.14% in Ribeirão
Preto35 and Belém, respectively.36 The prevalence of HIV mark-
ers for research purposes was 0.36% in Brazil, ranging from
0.18% in the state of Piauí to 1.32% in the state of Paraíba.16
Conclusion
The constant assessment of epidemiological data is of
paramount importance for the control and evaluation of both
blood donor recruitment strategies and public health poli-
cies as a whole. It is fundamental to implement policies
that use information as management tools to plan interven-
tion projects and follow-up actions in the area of transfusion
medicine, particularly for the recruitment of blood donors. The
presentation of data on serological ineligibility found in the
blood banks of the state of Minas Gerais shows us the peculiar-
ities of each region, thus contributing to health surveillance
measures and assisting to the blood-banking network and its
donor selection procedures aiming at improving transfusion
safety.
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